TransMedics Group Inc. (TMDX)
TransMedics: Every Hero Becomes A Bore At Last
TransMedics Group, Inc. faces significant challenges due to aircraft maintenance issues and rising aviation costs, leading to a 42% stock price drop and a HOLD rating. Revenue shortfall is attributed to a national decline in transplant volumes and reduced service component charges, impacting margins and overall financial performance. The company's aviation operations are struggling with unscheduled maintenance, reducing operational aircraft and causing missed revenue opportunities.
TransMedics Stock Falls as Q3 Earnings & Sales Miss Estimates
TMDX's third-quarter revenues increase with the utilization of the OCS across all three organs and additional revenues generated by its logistics services. Gross margin contracts.
Did TransMedics Group, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - TMDX
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of TransMedics Group, Inc. ("TransMedics Group, Inc.") (NASDAQ:TMDX) concerning possible violations of federal securities laws. On October 28, 2024, TransMedics reported disappointing financial results for the third quarter of 2024, missing analyst expectations on both the top and bottom lines.
TransMedics: Mistakes Have Been Made, Here's My Updated Outlook
TransMedics shares fell 25% pre-market after a disappointing Q3 report, missing revenue and EPS estimates, with management failing to manage expectations. Despite the poor quarter, the long-term opportunity remains large, and a good Q4 could significantly boost shares. Management's poor guidance and failure to prepare investors for the downturn were major issues, but the potential for growth still exists.
These Analysts Cut Their Forecasts On TransMedics Group Following Weak Results
TransMedics Group, Inc. TMDX posted downbeat quarterly results on Monday.
TransMedics Stock Crashes After Earnings Disappointment. Time to Load Up the Boat?
Is this the buy-the-dip opportunity investors have been waiting for?
TransMedics Group Posts Weak Results, Joins Harmonic, Crocs, D.R. Horton And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 50 points on Tuesday.
TransMedics Group, Inc. (TMDX) Q3 2024 Earnings Call Transcript
TransMedics Group, Inc. (NASDAQ:TMDX ) Q3 2024 Earnings Conference Call October 28, 2024 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group, Investor Relations Waleed Hassanein - President and Chief Executive Officer Stephen Gordon - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan William Plovanic - Canaccord Joshua Jennings - TD Cowen Ryan Daniels - William Blair Matthew O'Brien - Piper Sandler Suraj Kalia - Oppenheimer & Company David Rescott - Baird Mike Matson - Needham & Company Operator Good afternoon and welcome to the TransMedics Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
TransMedics (TMDX) Q3 Earnings and Revenues Miss Estimates
TransMedics (TMDX) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to loss of $0.12 per share a year ago.
TransMedics, F5 Lead Big After-Hours Earnings Winners, Losers
With earnings season in full swing, big winners and losers abound. TransMedics and F5 were notable movers Monday night.
Stay Ahead of the Game With TransMedics (TMDX) Q3 Earnings: Wall Street's Insights on Key Metrics
Evaluate the expected performance of TransMedics (TMDX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Transplant Logistic Service Business Likely to Aid TMDX's Q3 Earnings
Expanding transplant logistic service business is likely to have driven TransMedics' third-quarter 2024 performance.
